Solventum Corporation (SOLV) Stock Analysis
Recovery setup
Healthcare · Medical Instruments & Supplies
Hold if already holding. Not a fresh buy at $76.09, but acceptable to hold if already in. Reasons: Analyst target reached - limited upside remaining; V7 low-quality RISK_OFF penalty: -0.5 (Q=5.0).
Solventum is a global healthcare company spun off from 3M in 2024, with three segments: MedSurg (57.9% of 2025 sales; wound therapy, sterilization, IV management), Dental Solutions (16.2%; brackets, aligners, cements), and Health Information Systems (16.3%; physician... Read more
Hold if already holding. Not a fresh buy at $76.09, but acceptable to hold if already in. Reasons: Analyst target reached - limited upside remaining; V7 low-quality RISK_OFF penalty: -0.5 (Q=5.0). Chart setup: Death cross but MACD improving, RSI 81. Multiple concerning factors. Consider reducing position. | News modifier +2 (SELL_IF_HOLDING → HOLD_IF_HOLDING) Score 4.8/10, moderate confidence.
Passes 6/9 gates (clean insider activity, no SEC red flags, news events none recent, earnings proximity 80d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and favorable risk/reward ratio and death cross (50MA < 200MA). Suitability: moderate.
Recent Developments — Solventum Corporation
Latest news
- SOLV vs. HQY: Which Stock Is the Better Value Option? - Yahoo Finance — Yahoo Finance neutral
- Solventum (SOLV) Projected to Post Earnings on Tuesday - MarketBeat — MarketBeat neutral
- Solventum (SOLV) Tops Q1 Earnings and Revenue Estimates - Yahoo Finance — Yahoo Finance positive
- Solventum (NYSE:SOLV) Exceeds Q1 CY2026 Expectations - StockStory — StockStory positive
- Solventum gains after activist Trian sends letter urging changes (update) (SOLV:NYSE) - Seeking Alpha — Seeking Alpha positive
Generated 2026-05-20T21:56:22Z.
Thesis
Key Metrics
Quality Signals
Material Events(8-K, last 90d)
- 2026-03-24Item 5.02MEDIUMChief Accounting Officer Mary Wilcox notified Solventum on March 20, 2026 of her intent to retire following appointment of a successor. No successor named at time of filing; no disagreement cited.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
2 floor-breakers
Revenue shrinking — -3.0% YoY. Growth thesis broken unless recovery story develops.static
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $76.09, but acceptable to hold if already in. Reasons: Analyst target reached - limited upside remaining; V7 low-quality RISK_OFF penalty: -0.5 (Q=5.0). Chart setup: Death cross but MACD improving, RSI 81. Multiple concerning factors. Consider reducing position. | News modifier +2 (SELL_IF_HOLDING → HOLD_IF_HOLDING) Target $74.94 (-1.5%), stop $71.87 (−5.9%), A.R:R -0.4:1. Score 4.8/10, moderate confidence.
Take-profit target: $74.94 (-1.5% upside). Target $74.94 (-1.5%), stop $71.87 (−5.9%), A.R:R -0.4:1. Stop-loss: $71.87.
Analyst target reached - limited upside remaining; V7 low-quality RISK_OFF penalty: -0.5 (Q=5.0); Leverage penalty (D/E 1.1): -0.5.
Solventum Corporation trades at a P/E of 9.1 (forward 10.5). TrendMatrix value score: 6.7/10. Verdict: Hold.
21 analysts cover SOLV with a consensus score of 3.7/5. Average price target: $82.
What does Solventum Corporation do?Solventum is a global healthcare company spun off from 3M in 2024, with three segments: MedSurg (57.9% of 2025 sales;...
Solventum is a global healthcare company spun off from 3M in 2024, with three segments: MedSurg (57.9% of 2025 sales; wound therapy, sterilization, IV management), Dental Solutions (16.2%; brackets, aligners, cements), and Health Information Systems (16.3%; physician documentation, coding, revenue cycle software). Products are sold to hospitals, clinics and healthcare systems in 90+ countries; the company carries approximately $5B of debt from the spin-off.